Year in Review

In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes. Read More ›

Combining anti–PD-(L)-1 with chemotherapy for the treatment of patients with a high PD-L1 expression level did not improve survival compared with anti–PD-(L)-1 monotherapy. Read More ›

Treatment of patients with advanced PD-L1–high NSCLC with a combination of immune checkpoint inhibitors and chemotherapy resulted in comparable or better outcomes than immune checkpoint inhibitors alone; however, tolerability was a limiting factor for elderly patients. Read More ›

Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone. Read More ›

Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone. Read More ›

The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC. Read More ›

The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity. Read More ›

First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone. Read More ›

Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC. Read More ›

The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status. Read More ›

Page 2 of 7